市場調查報告書
商品編碼
524495

轉甲狀腺蛋白類澱粉沉積症 (ATTR):流行病學預測 ∼2027年

Transthyretin Amyloidosis (ATTR) - Epidemiology Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

主要7個國家 (7MM:美國·法國·德國·義大利·西班牙·英國·日本) 的轉甲狀腺蛋白類澱粉沉積症 (ATTR)的確診患病人數,預測在2016年時將達到19,160人。

本報告提供全球主要7個國家 (7MM) 的轉甲狀腺蛋白類澱粉沉積症 (ATTR)的流行病學預測相關分析,提供疾病概要和目前治療手法/演算法,全球整體及各國的患病人數與風險患者趨勢預測 (總計12年份),相關疾病的疫情趨勢等相關調查。

第1章 主要考察

第2章 疾病的背景情況和概要:轉甲狀腺蛋白類澱粉沉積症 (ATTR)

  • 簡介
  • ATTR的臨床性方面
  • ATTR的類型
  • 疾病的原因
  • ATTR的症狀
  • 發病狀態
  • ATTR的診斷方法
    • 症狀與hATTP澱粉樣變性重疊的疾病
    • 紅旗症狀與hATTR澱粉樣變性相關
    • 確認hATTR澱粉樣變性診斷
    • 評估TTR-FAP進展的工具
    • 腕隧道症候群的檢測工具

第3章 流行病學和患者人口

  • 分析的要點
  • 患者人口與預測變數
  • 主要7個國家 (7MM)的ATTR的確診患病人數
  • 主要7個國家 (7MM)的ATTR的確診患病人數:各類型

第4章 各國的流行病學情形:轉甲狀腺蛋白類澱粉沉積症 (ATTR)

  • 美國
    • ATTR的確診患病人數
    • ATTR的確診患病人數:各類型
    • ATTR可治療的病例數
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第5章 ATTR相關的腕隧道症候群:確診患者的手術數量

  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 附錄

  • 分析方法

第7章 DelveInsight的服務內容

第8章 免責聲明

第9章 關於DelveInsight

目錄
Product Code: DIEI0956

DelveInsight's 'Transthyretin Amyloidosis (ATTR) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Transthyretin Amyloidosis (ATTR) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Transthyretin Amyloidosis (ATTR) Understanding

The DelveInsight Transthyretin Amyloidosis (ATTR) epidemiology report gives a thorough understanding of the Transthyretin Amyloidosis (ATTR) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Transthyretin Amyloidosis (ATTR) in the US, Europe, and Japan. The report covers the detailed information of the Transthyretin Amyloidosis (ATTR) epidemiology scenario in seven major countries (US, EU5, and Japan).

Transthyretin Amyloidosis (ATTR) Epidemiology Perspective by DelveInsight

The Transthyretin Amyloidosis (ATTR) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Transthyretin Amyloidosis (ATTR) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Transthyretin Amyloidosis (ATTR) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Transthyretin Amyloidosis (ATTR) Detailed Epidemiology Segmentation

The Transthyretin Amyloidosis (ATTR) epidemiology covered in the report provides historical as well as forecasted Transthyretin Amyloidosis (ATTR) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Transthyretin Amyloidosis (ATTR) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Transthyretin Amyloidosis (ATTR) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Transthyretin Amyloidosis (ATTR) Epidemiology Report and Model provide an overview of the risk factors and global trends of Transthyretin Amyloidosis (ATTR) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Transthyretin Amyloidosis (ATTR) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Transthyretin Amyloidosis (ATTR)
  • The report provides the segmentation of the Transthyretin Amyloidosis (ATTR) epidemiology

Report Highlights

  • 11-Year Forecast of Transthyretin Amyloidosis (ATTR) epidemiology
  • 7MM Coverage
  • Total Cases of Transthyretin Amyloidosis (ATTR)
  • Total Cases of Transthyretin Amyloidosis (ATTR) according to segmentation
  • Diagnosed cases of Transthyretin Amyloidosis (ATTR)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Transthyretin Amyloidosis (ATTR)?
  • What are the key findings pertaining to the Transthyretin Amyloidosis (ATTR) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Transthyretin Amyloidosis (ATTR) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Transthyretin Amyloidosis (ATTR)?
  • What are the currently available treatments of Transthyretin Amyloidosis (ATTR)?

Reasons to buy

  • The Transthyretin Amyloidosis (ATTR) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Transthyretin Amyloidosis (ATTR) market
  • Quantify patient populations in the global Transthyretin Amyloidosis (ATTR) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Transthyretin Amyloidosis (ATTR) therapeutics in each of the markets covered
  • Understand the magnitude of Transthyretin Amyloidosis (ATTR) population by its epidemiology
  • The Transthyretin Amyloidosis (ATTR) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Transthyretin Amyloidosis (ATTR)

3. Transthyretin Amyloidosis (ATTR): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Transthyretin Amyloidosis (ATTR) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Transthyretin Amyloidosis (ATTR) Treatment and Management
  • 6.2. Transthyretin Amyloidosis (ATTR) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1 Transthyretin Amyloidosis (ATTR) Epidemiology in 7MM (2017-2030)
  • Table 2 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3 Transthyretin Amyloidosis (ATTR) Epidemiology in the United States (2017-2030)
  • Table 4 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 Transthyretin Amyloidosis (ATTR) Epidemiology in Germany (2017-2030)
  • Table 6 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 Transthyretin Amyloidosis (ATTR) Epidemiology in France (2017-2030)
  • Table 8 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 Transthyretin Amyloidosis (ATTR) Epidemiology in Italy (2017-2030)
  • Table 10 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 Transthyretin Amyloidosis (ATTR) Epidemiology in Spain (2017-2030)
  • Table 12 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 Transthyretin Amyloidosis (ATTR) Epidemiology in the United Kingdom (2017-2030)
  • Table 14 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15 Transthyretin Amyloidosis (ATTR) Epidemiology in Japan (2017-2030)
  • Table 16 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1 Transthyretin Amyloidosis (ATTR) Epidemiology in 7MM (2017-2030)
  • Figure 2 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3 Transthyretin Amyloidosis (ATTR) Epidemiology in the United States (2017-2030)
  • Figure 4 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 Transthyretin Amyloidosis (ATTR) Epidemiology in Germany (2017-2030)
  • Figure 6 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 Transthyretin Amyloidosis (ATTR) Epidemiology in France (2017-2030)
  • Figure 8 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 Transthyretin Amyloidosis (ATTR) Epidemiology in Italy (2017-2030)
  • Figure 10 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 Transthyretin Amyloidosis (ATTR) Epidemiology in Spain (2017-2030)
  • Figure 12 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 Transthyretin Amyloidosis (ATTR) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15 Transthyretin Amyloidosis (ATTR) Epidemiology in Japan (2017-2030)
  • Figure 16 Transthyretin Amyloidosis (ATTR) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report